Fan Qiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fan Qiao has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Chao Ye
Department of Cardiovascular Surgery, Changhai hospital affiliated to the Naval Medical University, Shanghai, 200433, China
1 shared publicationFanglin Lu
Department of Cardiovascular Surgery, Shanghai General Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China
1 shared publication- Fanglin Lu
Department of Cardiovascular Surgery, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China
1 shared publication - Fei Chen
Laboratory of Cardiac Structure and Function , Institute of Cardiovascular Diseases , West China Hospital , Sichuan University , Chengdu , Sichuan, China , scu.edu.cn
1 shared publication Hongjie Xu
National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, 210002, China
1 shared publicationJiajun Pan
Department of Cardiovascular Surgery, Changhai hospital affiliated to the Naval Medical University, Shanghai, 200433, China
1 shared publication
Latest Publications
- 3 June 2026
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 19 (1)
Transjugular Transcatheter Tricuspid Valve Implantation of Coronary Stent System for Creating a Rat Tricuspid Regurgitation Model
We aimed to establish a rat TR model to further investigate the mechanisms of right heart remodeling and organ damage induced by TR. Intervention group rats (n = 6) underwent coronary stent system implantation via transjugular approach. The control group (n = 6) underwent the same procedure, except for coronary stent implantation. All rats survived at 8 weeks follow-up postoperatively. TR occurred immediately after the implantation of coronary stent in the intervention group. The right ventricular fractional area change (FAC) decreased by 33.9% compared with baseline from 0.59 ± 0.11% to 0.39 ± 0.10% (P = 0.005) and the tricuspid annular plane systolic excursion (TAPSE) decreased by 36.8% from 2.42 ± 0.31 mm to 1.53 ± 0.45 mm at 8 weeks (P < 0.001). This animal model would be suitable to further investigate the mechanisms of right ventricular remodeling and other organ damage associated with TR.
- 3 June 2026
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 19 (1)
Transjugular Transcatheter Tricuspid Valve Implantation of Coronary Stent System for Creating a Rat Tricuspid Regurgitation Model
We aimed to establish a rat TR model to further investigate the mechanisms of right heart remodeling and organ damage induced by TR. Intervention group rats (n = 6) underwent coronary stent system implantation via transjugular approach. The control group (n = 6) underwent the same procedure, except for coronary stent implantation. All rats survived at 8 weeks follow-up postoperatively. TR occurred immediately after the implantation of coronary stent in the intervention group. The right ventricular fractional area change (FAC) decreased by 33.9% compared with baseline from 0.59 ± 0.11% to 0.39 ± 0.10% (P = 0.005) and the tricuspid annular plane systolic excursion (TAPSE) decreased by 36.8% from 2.42 ± 0.31 mm to 1.53 ± 0.45 mm at 8 weeks (P < 0.001). This animal model would be suitable to further investigate the mechanisms of right ventricular remodeling and other organ damage associated with TR.
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2026 (1) , 8817783
Transcatheter Tricuspid Valve Replacement in Patients After Prior Left‐Sided Valve Surgery: A Multicenter Retrospective Analysis
Background: Functional tricuspid regurgitation (TR) after previous left‐sided valve surgery (LSVS) represents a significant proportion of all isolated TR cases; tricuspid valve reoperation in such patients, often in the advanced stage of disease, is historically regarded as high‐risk. Percutaneous transcatheter–based therapies for TR emerge as a potential solution. We sought to verify the performance of the LuX‐Valve Plus system in patients with a history of LSVS. Methods: A post hoc analysis of patients enrolled in the first‐in‐man and confirmatory study and an investigator‐initiated trial of the LuX‐Valve Plus system was conducted. Multiple endpoints, including mortality, valve performance, and functional status, were compared between patients with or without a history of LSVS. Propensity score matching (PSM) was used to minimize baseline differences between groups. Results: The study included 153 patients, with 56 patients having prior LSVS. After PSM, there were a total of 46 matched pairs. All‐cause mortality at 6 months was similar between groups (2.38% vs. 0%, respectively). Less‐than‐moderate paravalvular leakage and central TR were consistently observed in approximately 85% and 95% of patients through 6 months. Patients after prior LSVS achieved similar functional outcome in terms of the proportion of patients in NYHA Class I–II at 6 months (81.25% vs. 95.83%, p = 0.221). The Kansas City Cardiomyopathy Questionnaire score improved significantly after the procedure. Conclusions: In this small‐scale study, transcatheter implantation of the LuX‐Valve Plus for TR appeared to be safe and effective in patients with a history of LSVS, showing lower short‐term mortality and a degree of TR correction comparable to surgical outcomes.
- 1 January 2026
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2026 (1) , 8817783
Open AccessTranscatheter Tricuspid Valve Replacement in Patients After Prior Left‐Sided Valve Surgery: A Multicenter Retrospective Analysis
Background: Functional tricuspid regurgitation (TR) after previous left‐sided valve surgery (LSVS) represents a significant proportion of all isolated TR cases; tricuspid valve reoperation in such patients, often in the advanced stage of disease, is historically regarded as high‐risk. Percutaneous transcatheter–based therapies for TR emerge as a potential solution. We sought to verify the performance of the LuX‐Valve Plus system in patients with a history of LSVS. Methods: A post hoc analysis of patients enrolled in the first‐in‐man and confirmatory study and an investigator‐initiated trial of the LuX‐Valve Plus system was conducted. Multiple endpoints, including mortality, valve performance, and functional status, were compared between patients with or without a history of LSVS. Propensity score matching (PSM) was used to minimize baseline differences between groups. Results: The study included 153 patients, with 56 patients having prior LSVS. After PSM, there were a total of 46 matched pairs. All‐cause mortality at 6 months was similar between groups (2.38% vs. 0%, respectively). Less‐than‐moderate paravalvular leakage and central TR were consistently observed in approximately 85% and 95% of patients through 6 months. Patients after prior LSVS achieved similar functional outcome in terms of the proportion of patients in NYHA Class I–II at 6 months (81.25% vs. 95.83%, p = 0.221). The Kansas City Cardiomyopathy Questionnaire score improved significantly after the procedure. Conclusions: In this small‐scale study, transcatheter implantation of the LuX‐Valve Plus for TR appeared to be safe and effective in patients with a history of LSVS, showing lower short‐term mortality and a degree of TR correction comparable to surgical outcomes.